435 related articles for article (PubMed ID: 32803712)
1. Triple-negative breast cancer: new treatment strategies in the era of precision medicine.
Wu SY; Wang H; Shao ZM; Jiang YZ
Sci China Life Sci; 2021 Mar; 64(3):372-388. PubMed ID: 32803712
[TBL] [Abstract][Full Text] [Related]
2. Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020.
Azim HA; Ghosn M; Oualla K; Kassem L
Breast J; 2020 Jan; 26(1):69-80. PubMed ID: 31872557
[TBL] [Abstract][Full Text] [Related]
3. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Le Du F; Eckhardt BL; Lim B; Litton JK; Moulder S; Meric-Bernstam F; Gonzalez-Angulo AM; Ueno NT
Oncotarget; 2015 May; 6(15):12890-908. PubMed ID: 25973541
[TBL] [Abstract][Full Text] [Related]
4. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
Huynh MM; Pambid MR; Jayanthan A; Dorr A; Los G; Dunn SE
Expert Opin Investig Drugs; 2020 Nov; 29(11):1199-1208. PubMed ID: 32869671
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy.
Bando Y; Kobayashi T; Miyakami Y; Sumida S; Kakimoto T; Saijo Y; Uehara H
J Med Invest; 2021; 68(3.4):213-219. PubMed ID: 34759133
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai X; Ni J; Beretov J; Graham P; Li Y
Cancer Lett; 2021 Jan; 497():100-111. PubMed ID: 33069769
[TBL] [Abstract][Full Text] [Related]
8. Recent therapeutic trends and promising targets in triple negative breast cancer.
Hwang SY; Park S; Kwon Y
Pharmacol Ther; 2019 Jul; 199():30-57. PubMed ID: 30825473
[TBL] [Abstract][Full Text] [Related]
9. Progress in systemic therapy for triple-negative breast cancer.
Mo H; Xu B
Front Med; 2021 Feb; 15(1):1-10. PubMed ID: 32789731
[TBL] [Abstract][Full Text] [Related]
10. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
11. The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification.
Weng L; Zhou J; Guo S; Xu N; Ma R
Cancer Cell Int; 2024 Mar; 24(1):120. PubMed ID: 38555429
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
Kalimutho M; Parsons K; Mittal D; López JA; Srihari S; Khanna KK
Trends Pharmacol Sci; 2015 Dec; 36(12):822-846. PubMed ID: 26538316
[TBL] [Abstract][Full Text] [Related]
13. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
14. Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions.
Hossain F; Majumder S; David J; Miele L
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359640
[TBL] [Abstract][Full Text] [Related]
15. Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy.
Kumar N; Raza M; Sehrawat S
Mol Cell Biochem; 2021 Nov; 476(11):4177-4189. PubMed ID: 34324118
[TBL] [Abstract][Full Text] [Related]
16. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.
Cheng L; Schneider BP; Li L
J Am Med Inform Assoc; 2016 Jul; 23(4):741-9. PubMed ID: 27107440
[TBL] [Abstract][Full Text] [Related]
17. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
18. Emerging Novel Therapeutics in Triple-Negative Breast Cancer.
Lyons TG; Traina TA
Adv Exp Med Biol; 2019; 1152():377-399. PubMed ID: 31456195
[TBL] [Abstract][Full Text] [Related]
19. Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
Telli M
Am Soc Clin Oncol Educ Book; 2014; ():e37-42. PubMed ID: 24857126
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
